GlassScriptPhysician profile
Justin Anderson
NPI 1700381548
$4,607.52
in general payments reported to CMS, 2019-2025
58 companies · $2,878 in 2025
The $2,878 reported for 2025 was more than what 92% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $174 · 2024: $1,556 · 2025: $2,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,607.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $563.23 | 2023-2025 | |
| Janssen Biotech, INC. | $407.62 | 2024-2025 | Rybrevant, Darzalex, Erleada |
| Merck Sharp & Dohme LLC | $386.33 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $279.64 | 2024-2025 | Tagrisso, Enhertu |
| Novocure INC. | $223.03 | 2023-2025 | Optune Lua (Novottf-200t), Optune |
| Abbvie INC. | $183.39 | 2024-2025 | |
| Incyte Corporation | $165.51 | 2024-2025 | Monjuvi, Pemazyre, Jakafi |
| Daiichi Sankyo INC. | $158.56 | 2024-2025 | Enhertu, Injectafer, Datroway |
| Genzyme Corporation | $124.91 | 2024-2025 | |
| Genentech USA, INC. | $111.66 | 2024-2025 | Tecentriq, Itovebi, Phesgo |
| E.R. Squibb & Sons, L.L.C. | $106.87 | 2024-2025 | Opdivo |
| Progenics Pharmaceuticals, INC. | $100.57 | 2023 | Pylarify |
| Pfizer INC. | $84.94 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.27 | 2024-2025 | |
| Emd Serono, INC. | $78.03 | 2024-2025 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.